meta
|
evidence
oncology
Living systematic review and meta-analysis
malignant mesothelioma (mMS) - 2nd line (L2)
2
multiple myeloma
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
Immunostimulant
vaccine
UV1 vaccine
UV1 vaccine plus nivolumab and ipilimumab
versus all
vs immune chekpoint inhibitors
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network